CariGenetics Partners With Concr Tech Firm
Concr — which was described as a “deeptech company dedicated to enabling precision medicine and improving drug development using predictive analytics and artificial intelligence [AI]” — announced its partnership with CariGenetics.
A spokesperson said, “Through this collaboration, Concr and CariGenetics will expand use of vital genetic and molecular data on Triple Negative Breast Cancer [TNBC] from the Caribbean region, filling a critical gap in diversity for global healthcare and the pharmaceutical industry.
“In a statement, Concr highlighted the importance of the high-quality and diverse datasets developed by CariGenetics, highlighting reliance on comprehensive data to effectively train algorithms that reflect the global population, minimising the biases often found in AI models reliant on limited datasets.”
“Including diverse data, especially data representing people who’ve historically been overlooked in research, is not just about making AI fairer, it’s essential to broaden our understanding of biology and science” said Concr’s CEO Dr Irina Babina.
“We are thrilled to partner with CariGenetics who are so uniquely positioned to address this critical need by generating data that supports more accurate, personalised therapy across diverse populations. While historical data brings valuable insights, deliberate prospective data collections like those at CariGenetics is how we advance the field.”
The spokesperson said, “By linking clinical, genetic, and molecular TNBC data from the Caribbean – a region historically underrepresented in genomics and AI research – CariGenetics is actively addressing these disparities, ensuring that AI-driven solutions in healthcare benefit populations globally.
“Concr also noted the increasing demand among pharmaceutical companies for robust and inclusive AI models to drive drug discovery and development. Many organisations are now appointing AI and data specialists to leadership roles to guide this strategic shift, underscoring the critical need for high-quality data such as that which CariGenetics is gathering.”
Dr. Carika Weldon, CEO of CariGenetics, commented on the collaboration: “We are thrilled to partner with Concr to ensure the Caribbean’s unique genetic data informs AI-driven advances in healthcare. Our mission is to bring the region to the forefront of precision medicine, so that the next generation of treatments is both more inclusive and effective for diverse populations.”
The spokesperson said, “Through this partnership, CariGenetics’ work will directly support the creation of AI models that enhance patient care for underrepresented populations. The collaboration is positioned to not only propel the future of AI-driven precision medicine but also to provide Caribbean communities with access to the latest advancements in personalised healthcare.
“For more information about CariGenetics and its partnership with Concr, please visit www.carigenetics.com.”
Read More About
Category: All, technology
